Dr. Markus Vallaster currently serves as the Vice President and Head of Clinical Development at Affini-T Therapeutics, Inc. an immune-oncology company focused on TCR T cell therapies that target oncogenic driver mutations such as KRAS and TP53 in patients with solid cancers. Prior to joining Affini-T, he held clinical development positions of increasing responsibility at major pharmaceutical companies. Dr. Vallaster’s expertise lies in stem cell transplant, cell therapies, and hemato-oncology.
